Increasing lymphoma cases are driving the Rituximab Biosimilars Market 2026

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Rituximab Biosimilars Market During The Forecast Period 2026–2030?

The rituximab biosimilars market size has seen rapid expansion in recent years. It is anticipated to grow from $3.42 billion in 2025 to $3.84 billion in 2026, at a compound annual growth rate (CAGR) of 12.5%. This growth observed in the historic period can be attributed to factors such as the high cost of originator rituximab, the increasing prevalence of non-hodgkin’s lymphoma, a growing incidence of chronic lymphocytic leukemia, rising awareness concerning autoimmune disease management, and limited access to advanced biologics.

The market for rituximab biosimilars is projected to expand significantly in the coming years. Its value is anticipated to reach $6.26 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.0%. This projected expansion during the forecast period stems from factors such as the introduction of novel biosimilar formulations, wider availability of subcutaneous delivery methods, greater uptake in developing regions, growing governmental and insurance backing for biosimilars, and their incorporation into hospital and specialized pharmacy initiatives. Key trends expected over this period encompass the increased acceptance of rituximab biosimilars in treating oncology and autoimmune conditions, the wider deployment of subcutaneous administration and pre-filled delivery mechanisms, a heightened demand for affordable monoclonal antibody substitutes, the expanding application of antibody-drug conjugates (ADCs) in targeted treatments, and improved distribution networks through hospitals and retail pharmacies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3430&type=smp

What Underlying Factors Are Accelerating The Growth Of The Rituximab Biosimilars Market?

The increasing occurrence of non-Hodgkin’s lymphoma (NHL) is projected to stimulate the expansion of the rituximab biosimilars market in the foreseeable future. Non-Hodgkin’s lymphoma is a form of cancer originating in lymphocytes, a type of white blood cell vital to the body’s immune system. The growing incidence of NHL is attributed to rising rates, particularly among older populations, alongside various lifestyle and environmental contributors. Rituximab Biosimilars offer an effective treatment, targeting and eliminating CD20-positive B cells, thereby lessening tumor burden, improving immune system function, and providing a more accessible and cost-effective therapeutic option for individuals with non-Hodgkin’s lymphoma (NHL), ultimately enhancing overall treatment efficacy and quality of life. For example, as reported by the American Cancer Society, a US-based cancer advocacy organization, in January 2024, approximately 80,620 individuals (comprising 44,590 men and 36,030 women) were anticipated to be diagnosed with non-Hodgkin lymphoma, with an estimated 20,140 deaths (11,780 men and 8,360 women). The lifetime probability of developing this cancer stands at approximately 1 in 42 for men and 1 in 52 for women. Consequently, the rising prevalence of non-Hodgkin’s lymphoma is fueling the growth of the rituximab biosimilars market. The increasing occurrence of autoimmune diseases is anticipated to drive the expansion of the rituximab biosimilars market moving forward. Autoimmune diseases are conditions where the body’s immune system erroneously attacks its own healthy tissues, perceiving them as foreign invaders. Rituximab biosimilars are utilized in the management of autoimmune diseases by specifically targeting B cells, which helps in reducing inflammation and mitigating autoimmune responses. For example, data from Arthritis Australia, an Australia-based non-profit organization, indicated in February 2024 that an estimated 562,378 Australians would be living with RA by 2025, constituting 14% of all arthritis cases that year. This figure is projected to increase by 33% to 748,721 individuals by 2040, signifying an additional 186,343 Australians affected by RA in 2040 compared to 2025. Hence, the increasing prevalence of autoimmune diseases is a key factor propelling the growth of the rituximab biosimilars market.

What Market Segments Are Evaluated Within The Rituximab Biosimilars Market?

The rituximab biosimilars market covered in this report is segmented –

1) By Route Of Administration: Subcutaneous, Intravenous

2) By Application: Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia, Rheumatoid Arthritis, Other Applications

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Mail Order

Subsegments:

1) By Subcutaneous: Pre-filled Syringes, Injection Pens

2) By Intravenous: IV Infusion Solutions, IV Push Formulations

What Industry Trends Are Redefining The Rituximab Biosimilars Market?

Leading companies operating in the rituximab biosimilars market are concentrating on developing innovative products through strategic partnerships to enhance accessibility and provide more affordable treatment alternatives for patients with various immunological and oncological conditions. Collaborations with established partners assist companies in accelerating commercialization, leveraging combined expertise in regulatory approvals and distribution, and effectively launching biosimilars, thereby increasing patient access and market penetration. For example, in July 2023, Dr. Reddy’s Laboratories partnered with Fresenius Kabi to commercialize its proposed rituximab biosimilar in the US. This partnership aims to introduce a biosimilar version of rituximab to the market, offering a more economical and accessible treatment option for patients. The presence of a rituximab biosimilar in the United States has the potential to expand access to this crucial treatment for patients suffering from various conditions, including rheumatoid arthritis, non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, pemphigus vulgaris, granulomatosis with polyangiitis, and microscopic polyangiitis.

Who Are The Top Market Participants Influencing The Rituximab Biosimilars Market?

Major companies operating in the rituximab biosimilars market are Novartis AG, Pfizer, BIOCAD, Shanghai Henlius Biotech Inc., Innovent Biologics Inc., Cadila Pharmaceuticals, Hetero Drugs Limited, Dr. Reddy’s Laboratories, Shanghai Fosun Pharmaceutical (Group) Co. Ltd., Reliance Life Sciences India, Zenotech Laboratories, Celltrion, Biocad, MABION S.A., Amgen, Teva Pharmaceuticals, Celltrion Healthcare, Coherus BioSciences, Aryogen Biopharma, TR-Pharm, Hikma Pharmaceuticals plc.

Read the full rituximab biosimilars market report here:

https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report

Which Region Is Projected To Dominate The Rituximab Biosimilars Market During The Forecast Period?

North America was the largest region in the rituximab biosimilars market in 2025. Middle East is expected to be the fastest-growing region in the rituximab biosimilars market report during the forecast period. The regions covered in the rituximab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Rituximab Biosimilars Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3430&type=smp

Browse Through More Reports Similar to the Global Rituximab Biosimilars Market 2026, By The Business Research Company

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Oncology Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Oral Biologics And Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795